Novel data with trastuzumab deruxtecan, sacituzumab govitecan, and ribociclib have demonstrated an influx of overall survival advantages compared with standard-of-care regimens across breast cancer patient subsets, including HER2-positive, hormone receptor–positive, and triple-negative disease.
The European Commission has approved sacituzumab govitecan-hziy for the treatment of adult patients with unresectable or metastatic hormone receptor–positive, HER2-negative breast cancer who have received endocrine-based therapy and at least 2 additional systemic therapies in the advanced setting
Erika P. Hamilton, MD, discusses the role of trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer; the evolution of CDK4/6 inhibitors in hormone receptor–positive disease; and how genetic testing can match patients with personalized therapies and support further precision medicine research.
Metastatic Castrate-resistant Prostate Cancer (mCRPC) Market openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ The "Global Breast Cancer Immunotherapy Market & Clinical Trials Forecast 2028" report has been added to ResearchAndMarkets.com s offering..